Daré Bioscience, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 26
- Market Cap
- -
Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Daré Bioscience, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06668896
Contraceptive Efficacy Study of Ovaprene
- Conditions
- Contraception
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Daré Bioscience, Inc.
- Target Recruit Count
- 656
- Registration Number
- NCT06127199
- Locations
- 🇺🇸
Precision Trials AZ, Phoenix, Arizona, United States
🇺🇸Del Sol Research Management, LLC, Tucson, Arizona, United States
🇺🇸Essential Health Access (Berkeley), Berkeley, California, United States
Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%
- Conditions
- Sexual Arousal Disorder
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Daré Bioscience, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05765487
- Locations
- 🇨🇦
Pharma Medica Research, Inc., Mississauga, Ontario, Canada
A Study of Diclofenac Gel in Women With Primary Dysmenorrhea
- Conditions
- Dysmenorrhea Primary
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Daré Bioscience, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05752526
- Locations
- 🇦🇺
PARC Clinical Research, Adelaide, Western Australia, Australia
A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women
- Conditions
- Vulvovaginal AtrophyVasomotor Symptoms
- Interventions
- Device: IVR Dose 1Device: IVR Dose 2Drug: Oral Reference
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Daré Bioscience, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT05418426
- Locations
- 🇦🇺
PARC Clinical Research, Melbourne, Australia
🇦🇺Keogh Institute for medical Research, Nedlands, Australia
- Prev
- 1
- 2
- Next
News
Daré Bioscience Receives $6 Million Grant Installment for Smart Drug Delivery Platform Development
Daré Bioscience received a $6 million non-dilutive grant installment, bringing total funding to $37.8 million of up to $49 million committed for DARE-LARC1 contraceptive development.
Daré Bioscience Fast-Tracks Sildenafil Cream Launch with Dual-Market Strategy for Women's Health
Daré Bioscience has unveiled a dual-path approach to make its proprietary Sildenafil Cream formulation available via prescription by Q4 2025, responding to healthcare community urging and women's demand.
XOMA Royalty Expands Portfolio to Over 120 Assets, Reports Financial Results for 2024
• XOMA Royalty doubled its portfolio to over 120 royalty assets through five strategic transactions in 2024, strengthening its position as a biotech royalty aggregator. • The company completed two whole company acquisitions and celebrated FDA approvals for Day One's OJEMDA™ (tovorafenib) and Zevra's MIPLYFFA™ (arimoclomol), generating significant milestone payments. • Despite reporting a net loss of $13.8 million for 2024, XOMA Royalty received $46.3 million in cash receipts and maintains over $100 million in cash, positioning it for sustainable cashflow from royalties.
Daré Bioscience and Theramex Partner to Develop Novel Biodegradable Contraceptive Implant
Daré Bioscience and Theramex have entered into a co-development agreement for Casea S, a first-in-category biodegradable contraceptive implant designed to last 18-24 months.
Sildenafil Cream Shows Consistent Efficacy for FSAD Across Patient Subgroups
Post-hoc analysis of the phase 2b RESPOND trial reveals that topical sildenafil cream, 3.6%, maintains efficacy for FSAD across various patient subgroups.
Daré Bioscience Advances Sildenafil Cream for Female Sexual Arousal Disorder
Daré Bioscience is moving forward with Phase 3 trials for Sildenafil Cream 3.6% to treat Female Sexual Arousal Disorder (FSAD).
Daré Bioscience Advances Women's Health Portfolio with Funding and Clinical Progress
• Daré Bioscience is progressing its hormone-free contraceptive, Ovaprene, in a Phase 3 efficacy study, boosted by a foundation grant to expand clinical sites. • Sildenafil Cream 3.6% for female sexual arousal disorder is advancing towards Phase 3 after constructive FDA discussions on trial design and endpoints. • DARE-HPV, a novel treatment for HPV-related cervical diseases, is set for a Phase 2 trial, supported by a $10 million ARPA-H award. • Activities are underway for Phase 2 and Phase 1 studies of DARE-VVA1 and DARE-PTB1, respectively, targeting dyspareunia and preterm birth prevention.